(Q45934900)

18 December 2017

title

Pharmacokinetic, pharmacodynamic, and safety profile of a new cholesteryl ester transfer protein inhibitor in healthy human subjects. (English)

1 reference

18 December 2017

human subject research project

main subject

0 references

1 reference

1 reference

R Wolk

1

1 reference

18 December 2017

D Chen

2

1 reference

18 December 2017

R W Clark

3

1 reference

18 December 2017

J Mancuso

4

1 reference

18 December 2017

P L Barclay

5

1 reference

18 December 2017

language of work or name

English

0 references

publication date

8 July 2009

1 reference

18 December 2017

Clinical Pharmacology & Therapeutics

published in

1 reference

18 December 2017

volume

86

1 reference

18 December 2017

issue

4

1 reference

18 December 2017

page(s)

430-437

1 reference

18 December 2017

High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies

cites work

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.120

Cholesteryl ester transfer protein: a novel target for raising HDL and inhibiting atherosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.120

Raising high-density lipoprotein in humans through inhibition of cholesteryl ester transfer protein: an initial multidose study of torcetrapib

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.120

Efficacy and safety of a novel cholesteryl ester transfer protein inhibitor, JTT-705, in humans: a randomized phase II dose-response study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.120

Multiple-dose pharmacodynamics and pharmacokinetics of anacetrapib, a potent cholesteryl ester transfer protein (CETP) inhibitor, in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.120

Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.120

Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.120

Torcetrapib and carotid intima-media thickness in mixed dyslipidaemia (RADIANCE 2 study): a randomised, double-blind trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.120

Effect of torcetrapib on the progression of coronary atherosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.120

Effects of torcetrapib in patients at high risk for coronary events

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.120

Increased high-density lipoprotein levels caused by a common cholesteryl-ester transfer protein gene mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.120

Accumulation of apolipoprotein E-rich high density lipoproteins in hyperalphalipoproteinemic human subjects with plasma cholesteryl ester transfer protein deficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.120

Effect of the cholesteryl ester transfer protein inhibitor, anacetrapib, on lipoproteins in patients with dyslipidaemia and on 24-h ambulatory blood pressure in healthy individuals: two double-blind, randomised placebo-controlled phase I studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.120

Efficacy and safety of the cholesteryl ester transfer protein inhibitor anacetrapib as monotherapy and coadministered with atorvastatin in dyslipidemic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.120

Inhibition of CETP by torcetrapib attenuates the atherogenicity of postprandial TG-rich lipoproteins in type IIB hyperlipidemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.120

Inverse relationship between blood levels of high density lipoprotein subfraction 2 and magnitude of postprandial lipemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.120

Inhibition of cholesteryl ester transfer protein increases serum apolipoprotein (apo) A-I levels by increasing the synthesis of apo A-I in rabbits

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.120

Effectiveness of inhibition of cholesteryl ester transfer protein by JTT-705 in combination with pravastatin in type II dyslipidemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.120

Radioimmunoassay studies of human apolipoprotein E.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.120

Effects of the cholesteryl ester transfer protein inhibitor torcetrapib on VLDL apolipoprotein E metabolism.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.120

Apolipoprotein E recycling: implications for dyslipidemia and atherosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.120

Inhibition of cholesteryl ester transfer protein by torcetrapib modestly increases macrophage cholesterol efflux to HDL.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.120

Structural and functional properties of human plasma high density-sized lipoprotein containing only apoE particles

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.120

Regulation of reconstituted high density lipoprotein structure and remodeling by apolipoprotein E.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.120

HDL from CETP-deficient subjects shows enhanced ability to promote cholesterol efflux from macrophages in an apoE- and ABCG1-dependent pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.120

Comparison of expression and regulation of the high-density lipoprotein receptor SR-BI and the low-density lipoprotein receptor in human adrenocortical carcinoma NCI-H295 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.120

Cholesteryl ester exchange protein in human plasma isolation and characterization

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.120

Effects of the cholesteryl ester transfer protein inhibitor torcetrapib on apolipoprotein B100 metabolism in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.120

inferred from DOI database lookup

7 January 2021

based on heuristic

Decreased post-prandial triglyceride response and diminished remnant lipoprotein formation in cholesteryl ester transfer protein (CETP) deficiency

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.120

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1038/CLPT.2009.120

1 reference

18 December 2017

1 reference

18 December 2017